

## AACR Bulletin Board

### Annual Meeting

The AACR's Annual Meeting is one of the largest and most important annual gatherings of scientists engaged in cancer research worldwide. The next Annual Meeting will take place in Washington, D. C., from April 20–24, 1996. The Chairperson of the Annual Meeting is Lorraine J. Gudas of the Cornell University Medical College. Dr. Gudas and her Program Committee have invited outstanding scientists in the field to organize plenary sessions, symposia, methods workshops, controversy sessions, and meet-the-expert sunrise sessions. The Committee has just completed the scheduling of proffered papers in minisymposia, poster discussion sessions, and poster sessions. The deadline for abstract submissions was December 1, 1995.

### Workshop on Methods in Clinical Cancer Research

This August the AACR and the American Society of Clinical Oncology (ASCO) will introduce a new, 6-day summer workshop on clinical research methods designed for both oncologists in training and senior investigators. The workshop will take place at the Inn at Prospector Square in Park City, Utah, from August 17–23, 1996. The overall goal of the workshop will be to educate clinical scientists in methods for clinical research and to encourage better clinical trial design so that new cancer treatments can be introduced more rapidly into general medical practice. Major support for this program has already been obtained from Bristol-Myers Squibb and Hoechst Marion Roussel Amgen, and a grant proposal has been submitted to the National Cancer Institute. Funds will be available to offset the registration fees and housing and subsistence expenses for 75 clinical trainees to attend the workshop. In addition, 25 clinical investigators at the level of junior faculty will be accepted to the workshop upon payment of a registration fee. (If additional funding is received, some travel support may be available for junior faculty.)

The Workshop Organizing Committee is chaired by Drs. Daniel D. Von Hoff (for AACR) and Charles A. Coltman, Jr. (for ASCO), both of the Cancer Therapy and Research Center in San Antonio, Texas. They will invite and select a distinguished faculty that will deliver over 20 hours of lectures on a variety of topics in the field and direct four 2-hour small group discussion sessions in which 25–30 participants will obtain practical training in subjects that are essential to the success of clinical trials. In addition, all participants will be responsible for the preparation and submission of a concept sheet for an actual clinical trial protocol. Faculty will review and provide detailed critiques of these concept sheets. ASCO

### AACR

The American Association for Cancer Research (AACR) was founded in 1907 to bring together active investigators of the cancer problem for the presentation and discussion of new findings and to foster advances in cancer research. Today the Association has more than 11,000 members working in all of the subdisciplines of cancer research in the United States, Canada, and more than 50 other countries. Information on AACR programs and activities can be obtained from

**American Association for  
Cancer Research  
Public Ledger Building  
150 South Independence Mall West  
Suite 816  
Philadelphia, PA 19106-3483  
Phone: (215) 440-9300  
Fax: (215) 440-9313**

The AACR welcomes applications for membership from the readership. Scientists engaged in all areas of cancer research are eligible for membership. There are three categories of membership: *active* membership, open to cancer researchers working in the Americas; *corresponding* membership, to those working outside the Americas; and *associate* membership, to graduate and medical students, postdoctoral fellows, and physicians-in-training. Further information on the qualifications for each category as well as the benefits of membership can be found on the application forms at the back of this issue.

will certify this workshop for Category 1 credits toward the AMA Physicians Recognition Award.

Information and application forms were mailed to AACR and ASCO members in March. Nonmembers should request brochures from the AACR office. The deadline for receipt of applications will be April 25, 1996.

### AACR Special Conferences in Cancer Research

A number of meetings are now being organized in the AACR's new series of smaller scientific meetings. Following are the topics, dates, locations, and program committees for some of these meetings. When full details of each meeting are available, AACR members will be the first to receive complete brochures and application forms for participation in these important conferences. Nonmembers may receive this information by sending their names and addresses to Meetings Mailing List, American Association for Cancer Research, Public Ledger Building, 150 South Independence Mall

West, Suite 816, Philadelphia, PA 19106-3483. Telephone: (215) 440-9300. FAX: (215) 440-9313. E-Mail: aacr@aol.com.

#### June 8–12, 1996

Inducible Genomic Responses

*Chairpersons:*

WILLIAM T. BECK, Memphis, TN  
JOHN A. HICKMAN, Birmingham, England  
RICHARD I. MORIMOTO, Evanston, IL  
Skamania Lodge, Stevenson (Columbia River Gorge), WA

#### October 2–6, 1996

Novel Approaches in Blood and Marrow Transplantation

Second Annual Meeting of the American Society for Blood and Marrow Transplantation

*Chairpersons:*

O. MICHAEL COLVIN, Durham, NC  
BRUCE R. BLAZAR, Minneapolis, MN  
Hotel Del Coronado, San Diego, CA

#### October 19–23, 1996

Programmed Cell Death

*Chairperson:*

STANLEY J. KORSMEYER, St. Louis, MO  
The Sagamore Resort, Bolton Landing (Lake George), NY

#### January 10–14, 1997

Basic and Clinical Aspects of Lymphoma  
Joint AACR/American Society of Clinical Oncology Conference

*Chairpersons:*

JOSEPH R. BERTINO, New York, NY  
JAMES O. ARMITAGE, Omaha, NE  
Stouffer Renaissance Esmeralda Resort, Indian Wells (Palm Springs), CA

#### February 13–16, 1997

Growth Factors and Cancer  
Joint Meeting with Australian Cancer Society

*Chairpersons:*

ANTONY BURGESS, Parkville, Victoria, Australia  
ROBERT S. COFFEY, Nashville, TN  
ASHLEY R. DUNN, Parkville, Victoria, Australia  
RAYMOND L. WHITE, Salt Lake City, UT  
Erskine House, Lorne, Victoria, Australia

#### February 23–27, 1997

Cell Signaling and Cancer Treatment  
Conference Held in Collaboration with:  
British Association for Cancer Research  
European Organization for Research and Treatment of Cancer (PAMM Group)

German Cancer Society  
Austrian Biochemical Society

*Chairpersons:*

HANS H. GRUNICKE, Innsbruck, Austria  
GARTH POWIS, Tucson, AZ  
PAUL WORKMAN, Macclesfield, England  
Congress Center, Seefeld, Austria

*An Outstanding Opportunity for Researchers at the Level of Fellow or Junior Faculty  
to Learn The Essentials of Clinical Trials Design*



**THE AMERICAN ASSOCIATION FOR CANCER RESEARCH  
AND THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY  
PRESENT**



**Methods in Clinical Cancer Research**

August 17-23, 1996, Inn at Prospector Square, Park City, Utah

**Supported by Generous Grants from Amgen, Inc., Bristol-Myers Squibb Oncology, and Hoechst Marion Roussel  
Additional Support Pending from the National Cancer Institute**

- A series of lectures by leaders in the field covering all elements of clinical trials design
- Small group discussion sessions on important techniques in clinical research
- Detailed critique of clinical trial protocol concept sheet developed by each participant
- Category I CME credits through ASCO
- Waiver of Registration Fees and Partial Travel Support for Oncology Fellows
- Extended Application Deadline: April 30, 1996

**PROGRAM COMMITTEE**

**AACR**

Daniel D. Von Hoff, *Chairperson*  
David S. Alberts  
Gary M. Clark  
Merrill J. Egorin  
Sandra J. Horning

**ASCO**

Charles A. Coltman, Jr., *Chairperson*  
Janice P. Dutcher  
Michael A. Friedman  
Steven Piantadosi  
Mark J. Ratain

**FACULTY**

DAVID S. ALBERTS/ Tucson, AZ  
OTIS W. BRAWLEY/ Bethesda, MD  
GARY M. CLARK/ San Antonio, TX  
JERRY M. COLLINS/ Rockville, MD  
CHARLES A. COLTMAN, JR./ San Antonio, TX  
JOHN J. CROWLEY/ Seattle, WA  
ROBERT T. DORR/ Tucson, AZ  
JANICE P. DUTCHER/ Bronx, NY  
MERRILL J. EGORIN/ Baltimore, MD  
SUSAN S. ELLENBERG/ Rockville, MD  
CHARLES K. GRIESHABER/ Rockville, MD

WAUN KI HONG/ Houston, TX  
SANDRA J. HORNING/ Palo Alto, CA  
M. MARGARET KEMENY/Manhasset, NY  
ALBERT F. LOBUGLIO/ Birmingham, AL  
CAROL M. MOINPOUR/ Seattle, WA  
STEVEN PIANTADOSI/ Baltimore, MD  
GINA P. PETRONI/ Durham, NC  
MARK J. RATAIN/ Chicago, IL  
G. MARIE SWANSON/ East Lansing, MI  
IAN F. TANNOCK/ Toronto, Ontario, Canada  
DANIEL D. VON HOFF/ San Antonio, TX

*Additional Faculty To Be Announced*

**SESSION TOPICS**

**Lectures**

Basics of Phase I Clinical Trials  
Design and Conduct of Phase II and III Clinical Trials  
Ethics, Quality Assurance, and Recruitment  
Special Clinical Trial Design Problems  
Design of Trials of Preventive Agents

**Small Group Discussions**

Statistical Methods  
Basic Clinical Pharmacology  
Special Problems in Clinical Trial Design of Cytostatic Agents  
New Measures of Outcome: Quality of Life and Clinical Benefit

---

Further Information and Application Forms Available from  
American Association for Cancer Research • Public Ledger Building, Suite 816 • 150 S. Independence Mall West  
Philadelphia, PA 19106-3483 • Telephone: (215) 440-9300 • FAX: (215) 440-9313 • E-mail: aacr@aol.com  
American Society of Clinical Oncology • 225 Reinekers Lane, Suite 650 • Alexandria, VA 22314  
Telephone: (703) 299-1070 • FAX: (703) 299-1044 • E-mail: kaminsk@asco.org

## Instructions for Authors

### Scope

*Clinical Cancer Research*, a journal of the American Association for Cancer Research, publishes original articles describing clinical research on the cellular and molecular characterization, prevention, diagnosis, and therapy of human cancer. Its focus is on innovative clinical research and translational research which bridges the laboratory and the clinic. *Clinical Cancer Research* is especially interested in clinical trials evaluating new treatments for cancer; research on molecular abnormalities that predict incidence, response to therapy, and outcome; and laboratory studies of new drugs and biological agents that will lead to clinical trials in patients.

Specific areas of interest include clinical and translational research in: molecular pharmacology and chemotherapy; drug sensitivity and resistance; tumor immunology and immunotherapy; radiobiology and radiation oncology; solid tumor oncology; hematological malignancies; surgical oncology; pediatric oncology; molecular oncology and cancer genes; pathology, markers, and prognostic indicators; growth factors, cytokines, and signal transduction; bone marrow transplantation; gene therapy; cancer endocrinology; cell adhesion, invasion, and metastasis; prevention of primary and recurrent cancer; differentiation and cell death; clinical genetics; and detection of minimal disease.

### Editorial Policy

When a manuscript is received for consideration, the Editors assume that no similar paper has been or will be submitted for publication elsewhere. Further, it is understood that all authors listed on a manuscript have agreed to its submission. The signature of the corresponding author on the letter of submission signifies that these conditions have been fulfilled.

Journal policy requires that authors, reviewers, and Associate Editors reveal in a letter to the Editor-in-Chief any relationships that they have that could be construed as causing a conflict of interest with regard to a manuscript under review. The letter should include a statement of any financial relationships with commercial companies involved with a product under study.

Upon acceptance, authors must transfer copyright to the American Association for Cancer Research, Inc., the copyright owner of the journal, prior to publication. The Editors endorse the principles embodied in the Declaration of Helsinki and expect that all investigations involving humans will have been performed in accordance with these principles. To obtain a copy of the Helsinki Declaration, please contact the World Medical Association, 28, Ave. des Alpes, F-01210, Ferney-Voltaire, France. For animal experimentation reported in the journal, it is expected that investigators will have observed the *Interdisciplinary Principles and Guidelines for the Use of Animals in Research, Testing, and Education* issued by the New York Academy of Sciences' Ad Hoc Committee on Animal Research, a copy of which is available for \$5.00 from the Marketing Department, New York Academy of Sciences, 2 East 63rd Street, New York, NY 10021-7289. All human and animal studies must

have been approved by the investigator's Institutional Review Board.

### Review Process

The review process, expedited by fax transmission and overnight mail service, is conducted as rapidly as possible. Each submitted manuscript is reviewed by at least two experts in the field of investigation. If the authors are invited to submit a revised manuscript for an expedited further review, the revised version must be submitted within three months.

### Manuscript Submission

Send manuscripts to John Mendelsohn, M.D., Editor-in-Chief, *Clinical Cancer Research*, at Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021. Submit four original sets (not photocopies) of figures along with four copies of the manuscript. If a manuscript is closely related to papers that are in press or have been submitted elsewhere, please provide copies of those papers with your submission.

Advances in Brief will be reserved for concise, definitive reports of novel observations and discoveries that have unusual importance. A request for consideration for Advances in Brief should be included in the letter of submission. A Minireview is a brief analysis (typically 3-4 printed pages) of a focused, timely research topic, aimed at a multidisciplinary audience. Minireviews and Controversies in *Clinical Cancer Research* that are submitted or solicited will undergo editorial review. The Editors welcome Letters to the Editor, which will be published if they are determined to be appropriate.

The letter of submission should suggest the Associate Editor (or Editor-in-Chief) who will serve as primary reviewer of the manuscript. In addition, we invite authors to provide the names, addresses, and telephone/fax numbers of up to five potential reviewers who are not current or recent collaborators or advisors in the area under investigation.

For both original and revised submissions, we cannot guarantee that manuscripts and illustrations will be returned to the author.

### Format

Manuscripts must be written succinctly in clear, grammatical English. Define abbreviations in an inclusive footnote to the text. Double-space on 8 1/2 x 11-inch paper. Dot-matrix printing is not acceptable. The format is as follows:

1. Title page, including title, authors and their institutions, research support, and address plus telephone/fax numbers of the corresponding author;
2. A running title of fewer than 50 characters;
3. Three to five key words that do not appear in the title;
4. Abstract, of not more than 250 words, stating briefly the objectives, methods, results, and conclusions of the study;
5. Text arranged in this order: Introduction, Methods, Results, Discussion, Acknowledgments, References;

6. Footnotes, on a page separate from the text. Designate footnotes consecutively with superscript Arabic numerals;
7. Tables, on pages separate from the text, with descriptive titles and legends that make the data understandable without reference to the text;
8. Figure legends, on pages separate from the text, with descriptive titles and explanations to make the data understandable without reference to the text. Define all symbols and include staining for halftones where applicable;
9. Figures.

---

### References

Include only those articles that have been published or are in press. Unpublished data or personal communications must be cited as footnotes to the text. Personal communications should be substantiated by a letter of permission. Number references in the order of their first mention in the text. Cite only the number assigned to the reference. References must be double-spaced.

### SAMPLE REFERENCES:

1. Shaffer, D. W., Smith, L. S., Burris, H. A., Clark, G. M., Eckardt, J. R., Fields, S. M., Weiss, G. R., Rinaldi, D. A., Bowen, K. J., Kuhn, J. G., and Von Hoff, D. D. A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies. *Cancer Res.*, 53: 5929-5933, 1993.
2. Dimaggio, J. J., Scheinberg, D. A., and Houghton, A. N. Monoclonal antibody therapy of cancer. *In*: H. M. Pinedo, B. A. Chabner, and D. L. Longo (eds.), *Cancer Chemotherapy and Biological Response Modifiers Annual*, Vol. 11, pp. 177-203. Amsterdam: Elsevier Science Publishers B. V., 1990.

---

### Figures

Provide four original sets of figures (whether line-cut drawings or halftones). Each sorted set should be in a separate labeled envelope, for distribution to reviewers. A typed label placed on the reverse side of each figure should contain the first author's name, figure number, and an arrow indicating top of figure. Letters and numbers on figures should not be smaller than 6-point or larger than 12-point type. All figures will be published at a width of approximately 3 inches (8 cm) unless

the author requests a greater width. Use tissue overlays to indicate important areas of the photographs that must be reproduced with greater fidelity.

Authors are encouraged to submit color figures. The expense of reproducing color photographs must be offset partially by the author. In 1996, the cost of color reproduction charged to authors will be \$975 per color figure. Submit color figures on flexible backing.

---

### Proofs

Page proofs must be returned to the office of the American Association for Cancer Research within 24 hours of receipt. Return proofs by overnight mail. **Proofs not received by the deadline will be published without the authors' corrections.** Accepted manuscripts are regarded as final copy and should not be altered substantially in proof. Extensive alterations could cause publication delays, and authors will be charged for excessive alterations in proof.

---

### Typesetting Manuscripts from Computer Disks

*Clinical Cancer Research* welcomes disks to expedite production of accepted manuscripts. If your article is accepted for publication, you will receive instructions regarding disk submission. It is the author's responsibility to ensure that the material on the disk matches the final accepted version of the manuscript.

---

### For more information, contact:

John Mendelsohn, M.D., Editor-in-Chief, *Clinical Cancer Research*, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, Telephone 212-639-6317, Fax 212-717-3629

or:

Publications Department, American Association for Cancer Research, Public Ledger Building, Suite 816, 150 South Independence Mall West, Philadelphia, PA 19106-3483, Telephone 215-440-9300, Fax 215-440-9355.



# AMERICAN ASSOCIATION FOR CANCER RESEARCH

## GUIDELINES FOR APPLICATION FOR ACTIVE AND CORRESPONDING MEMBERSHIP

### BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific society of over 11,000 laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage the presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

Members of the AACR enjoy the following benefits:

1. the privilege of sponsoring a proffered paper (abstract) for consideration for presentation at the AACR annual meeting;
2. an advance copy of the Program and *Proceedings of the American Association for Cancer Research* that contains over 4,000 abstracts of proffered papers presented at the annual meeting;
3. reduced registration rates at annual meetings;
4. priority notice of small, focussed meetings in the AACR's exciting series of Special Conferences in Cancer Research;
5. substantially reduced registration rates for Special Conferences;
6. opportunities for participation in AACR meetings in North America and abroad with other scientific societies around the world;
7. receipt of AACR Newsletters and other important announcements;
8. early notification of and reduced rates for participation in the AACR Employment Register;
9. an up-to-date Membership Directory of over 11,000 member researchers in the cancer field;
10. the professional benefits of the AACR's public education activities concerning funding for cancer research and press coverage of the latest research findings;
11. the opportunity to participate in three Summer Workshops that foster knowledge in the cancer field for young investigators;
12. the facilitation of informal scientific exchange with leading researchers in the cancer field; and
13. many more ongoing benefits.

### QUALIFICATIONS FOR MEMBERSHIP

**Active** membership in the AACR is open to investigators who live in the Americas. Individuals who have conducted two years of research resulting in peer-reviewed publications relevant to cancer, or who have made substantial contributions to cancer research in an administrative or educational capacity, are eligible. If a candidate has conducted research in an area of biomedical science related to cancer, he or she will qualify for membership. Evidence of patents relevant to cancer research may be submitted as qualifications for membership in lieu of peer-reviewed publications.

**Corresponding** membership is open to persons who are not residents of the Americas. The qualifications for corresponding membership are the same as those indicated above for active membership. Visiting scientists from outside the Americas who intend to return to their countries of origin by the anticipated time of election should apply for corresponding membership. All other visiting scientists should apply for active membership and transfer to corresponding status upon leaving the Americas.

Graduate and medical students, postdoctoral fellows, and physicians in training who do not yet meet the above qualifications for active or corresponding membership should apply for **associate** membership. Forms for associate membership are available from the AACR Office.

### PROCEDURES FOR APPLICATION

There are three deadlines for the receipt of a membership application: January 1, May 1, and September 1 of each year. The Membership Committee will review all complete applications for active membership that have been received by these deadlines and will submit recommendations on each candidate to the Board of Directors which formally elects all members. The same procedure is followed by the Special Memberships

Committee which receives applications for corresponding membership. Candidates will be notified according to the following schedule:

Receipt of Application in AACR Office	Notification of Candidate
January 1	March
May 1	July
September 1	November

A complete application consists of the following material:

1. 6 copies of the form on the opposite side of this page, with all requested information provided.
2. 5 copies of the candidate's most current curriculum vitae and bibliography.
3. 5 copies of a letter of recommendation from a nominator who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). This letter should describe the candidate's achievements in laboratory research, clinical investigations, or epidemiological research, and it should affirm that this research adheres to accepted ethical scientific standards. —OR— The nominator may supply the responses requested at the bottom of the application form in the section entitled "STATEMENT OF SUPPORT" (at least one copy of the form must be the signed original).
4. 5 copies of a letter of recommendation as described in Item 3 above from a seconder who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). —OR— The seconder may supply the responses requested at the bottom of the application form in the section entitled "STATEMENT OF SUPPORT" (at least one copy of the form must be the signed original).
5. 5 reprints of each of two publications on which the candidate appears as author. As noted above, evidence of patents developed by the candidate may be submitted in lieu of one or both of the publications. If submitting patents, supply patent number and year awarded.

All material should be collated into five complete sets with the original application form as a covering document and sent to the address given below. Questions regarding procedures for membership application may also be directed to the following address:

American Association for Cancer Research  
Public Ledger Building, Suite 816  
150 S. Independence Mall West  
Philadelphia, PA 19106-3483  
Phone: 215/440-9300  
FAX: 215/440-9313  
E-mail: aacr@aol.com

### RESPONSIBILITIES OF MEMBERSHIP

Candidates should be aware of the following responsibilities of membership in the AACR. Active members must pay annual dues. In 1996 annual dues for active members are \$160, \$95 of which is designated for AACR journal subscriptions. Newly elected members of the AACR who have already purchased subscriptions to *Cancer Research*, *Clinical Cancer Research*, *Cell Growth & Differentiation*, or *Cancer Epidemiology, Biomarkers & Prevention* at the higher, nonmember rates will receive reimbursement of the unused portion of those subscriptions once their first year's membership dues are paid in full.

Corresponding members are required to pay dues (\$80 in 1996) and may, if they wish, subscribe to *Cancer Research*, *Clinical Cancer Research*, *Cell Growth & Differentiation*, or *Cancer Epidemiology, Biomarkers & Prevention* at reduced member rates.

Applicants elected in March will be responsible for payment of that year's dues; applicants elected in July and November will pay dues for the following year. Applicants elected in March and July will be eligible to sponsor an abstract for the next annual meeting. Every effort will be made to afford the same opportunity to applicants elected in November.

Margaret Foti, Ph.D.  
Executive Director





# AMERICAN ASSOCIATION FOR CANCER RESEARCH

## GUIDELINES FOR APPLICATION FOR ASSOCIATE MEMBERSHIP

### QUALIFICATIONS FOR MEMBERSHIP

Associate membership is open to graduate students, medical students, postdoctoral fellows, and physicians in training who are following a course of study or who are working in a research program relevant to cancer. Scientists in training who already have a substantial record of publications may wish to apply for active or corresponding membership which confers full benefits of membership.

### BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific society consisting of laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world. Associate members of the AACR enjoy the following benefits:

1. the privilege of sponsoring a proffered paper (abstract) for consideration for presentation at the AACR annual meeting provided that (a) the associate member is the presenter of the paper and (b) an active, corresponding, emeritus, or honorary member in good standing of the AACR also signs the abstract of the paper in support of the work. (In this instance, the member who cosigns the abstract does not lose his or her own sponsorship privilege.);
2. an advance copy of the scientific Program and (if one has been purchased by the associate member) the *Proceedings of the American Association for Cancer Research* that contains over 4,000 abstracts of proffered papers presented at the annual meeting;
3. the privilege of registering for the annual meeting at the low associate member rate;
4. preferred access to the AACR Employment Register;
5. optional subscriptions to the Association's high-quality journals *Cancer Research*, *Clinical Cancer Research*, *Cell Growth & Differentiation*, and *Cancer Epidemiology, Biomarkers & Prevention* at reduced member rates;
6. priority notification of events in the AACR's series of special conferences on timely subjects in the field;
7. substantially reduced registration rates at special conferences;
8. the receipt of AACR newsletters, meeting announcements, and an up-to-date Membership Directory;
9. the opportunity to participate in three Summer Workshops that foster knowledge in the cancer field for young investigators; and
10. the facilitation of informal scientific exchange with leading researchers in the cancer field.

### PROCEDURES FOR APPLICATION

Persons wishing to apply for associate membership must use the official application form on the reverse side of these instructions. Each candidate for associate membership must be nominated by an active, corresponding, emeritus, or honorary member in good standing of the AACR. Three completed copies of the form should be submitted; at least

one of these copies must carry the original signatures of both the candidate and the nominator. The application form may be submitted to the Association Office at any time.

After review of applications for associate membership, the Executive Director will notify candidates of their election or deferral within one month of the receipt of the application form. A check for one year's dues payment must accompany the application. Dues are currently \$35 for associate members residing in the Americas and \$45 for residents of other countries. This fee will be refunded to any candidate deemed to be ineligible for associate membership. Checks should be in U.S. currency, made payable to AACR, Inc., and drawn on a U.S. bank. Send the three copies of the application form and the \$35 or \$45 dues payment to:

American Association for Cancer Research  
Public Ledger Building, Suite 816  
150 S. Independence Mall West  
Philadelphia, PA 19106-3483  
Phone: 215/440-9300  
FAX: 215/440-9313  
E-mail: aacr@aol.com

### RESPONSIBILITIES OF MEMBERSHIP

Associate members must pay annual dues in an amount to be determined by the AACR Board of Directors. Dues for 1995 and 1996 have been set at \$35 per year for residents of the Americas and \$45 for residents of other countries. If an application is submitted by August 31, the accompanying dues payment will be credited to the current year. Candidates submitting applications between September 1 and December 31 may indicate whether they wish their dues payments credited to the current or forthcoming year. Candidates should be aware, however, that associate members may sponsor an abstract for the annual meeting only if their dues for the current year are paid. For example, an associate member submitting an abstract in November 1995 for the forthcoming annual meeting must have paid dues for 1995. Any newly elected associate members of the AACR who have already purchased subscriptions to *Cancer Research*, *Clinical Cancer Research*, *Cell Growth & Differentiation*, or *Cancer Epidemiology, Biomarkers & Prevention* at the higher, nonmember rate will receive a refund for the unused portion of that subscription upon receipt of their payment for a member's subscription.

Each Fall the AACR will send to current associate members an invoice for dues for the forthcoming year. Payment of this invoice must be accompanied by a statement signed by the associate member's current registrar, dean, or department head, verifying the member's current academic status. The Association's By-Laws state that dues are payable for each year in advance by January 1 of the year to which they should be applied. An individual may be an associate member for a maximum of five years. Each year in which an individual pays dues will count as one full year of associate membership. Thus, an associate member who pays dues for 1995 may retain associate membership until December 31, 1999. The Board of Directors may terminate the membership of an associate member whose dues are in arrears for two years.

Margaret Foti, Ph.D.  
Executive Director

# AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC.

Public Ledger Building · Suite 816 · 150 S. Independence Mall West · Philadelphia, PA 19106-3483

## APPLICATION FOR ASSOCIATE MEMBERSHIP

NAME OF CANDIDATE: \_\_\_\_\_ DATE OF BIRTH: \_\_\_\_\_  
LAST FIRST M.I.

INSTITUTIONAL AFFILIATION: \_\_\_\_\_

INSTITUTIONAL ADDRESS: \_\_\_\_\_

(City) (State/Province) (Country) (Postal Code)

TELEPHONE NUMBER: \_\_\_\_\_ FAX NUMBER: \_\_\_\_\_

PRESENT ACADEMIC STATUS/TITLE (Please check only one): E-MAIL NUMBER (CARRIER): \_\_\_\_\_

\_\_\_\_ Graduate Student                      \_\_\_\_ Medical Student  
\_\_\_\_ Physician in Training                  \_\_\_\_ Postdoctoral Fellow

PRIMARY FIELD OF RESEARCH (Please check only one):

\_\_\_\_ Biochemistry and Biophysics                  \_\_\_\_ Biostatistics                      \_\_\_\_ Carcinogenesis  
\_\_\_\_ Cellular Biology and Genetics                  \_\_\_\_ Clinical Investigations                  \_\_\_\_ Endocrinology  
\_\_\_\_ Epidemiology                                  \_\_\_\_ Immunology                      \_\_\_\_ Molecular Biology and Genetics  
\_\_\_\_ Preclinical Pharmacology and                  \_\_\_\_ Virology                                  \_\_\_\_ Other: \_\_\_\_\_  
Experimental Therapeutics (Please specify)

ACADEMIC DEGREES (Please indicate degree(s) acquired to date along with the name of the academic institution and date of receipt. Provide information on degree currently being sought and the anticipated date of completion of this degree program.)

RELEVANT RESEARCH EXPERIENCE NOT RELATED TO COURSE WORK (Please list most recent first.)

PUBLICATIONS (List the authors, title, journal, volume, inclusive pages, and year of any article in a peer-reviewed journal on which the candidate appears as an author. Do not list abstracts. Continue on a separate sheet, if necessary.)

CANDIDATE NOMINATED BY\*: \_\_\_\_\_

(Please print)

### SIGNATURES

I hereby apply for associate membership in the American Association for Cancer Research. I have read the instructions on the reverse side of this form, and I understand the privileges and responsibilities of this class of membership. I certify that the statements on this application are true.

Signature of Candidate: \_\_\_\_\_ Date: \_\_\_\_\_

I recommend this candidate for associate membership in the American Association for Cancer Research. To the best of my knowledge, the candidate is qualified for this class of membership, and the statements on this application are true.

Signature of Nominator\*: \_\_\_\_\_ Date: \_\_\_\_\_

Submit three copies of this form. At least one copy must contain the original signatures of the candidate and the nominator. Enclose a check in U.S. funds, made payable to AACR, Inc., and drawn on a U.S. bank for one year's dues. Dues are currently \$35 for associate members residing in the Americas and \$45 for residents of other countries.

Check one of the following boxes only if this form is being submitted between September 1 and December 31:

The enclosed dues payment should be applied to the  current  forthcoming calendar year.

(NOTE: If dues are applied to the forthcoming year, membership will take effect on January 1, but the candidate will not be eligible to sponsor an abstract for presentation at the annual meeting in March on April of that year.) See Guidelines for Application on the reverse side of this form for further instructions.

\*Nominator must be active, corresponding, emeritus, or honorary member of the AACR.

## Guidelines for Submitting Disks to American Association for Cancer Research Publications

The word processing packages that we prefer are as follows:

MacWrite	WordPerfect (DOS, Windows, and Macintosh)
Microsoft Word (DOS, Windows, and Macintosh)	XyWrite (DOS and Windows)

Also acceptable:

Ability	Mass 11	SoloWriter
AmiPro	MS Windows Write	Sprint
A <sub>M</sub> S-TeX	MS Works	Stx
Appleworks	MS Works WP Mac	SunWrite
ArborTeX	Multimate	Symphony
ArborText	Multimate Advantage	TEX
ClarisWorks WP	Nibia	TeX78
CPT 8000	Nisus (to ASCII file)	Text EXecutive
CTOS	Notewriter	Textures
Diablo	Obun	Total Word
DisplayWrite	OfficeWriter	Troff
Duet	PC Write	μTeX
Einstein	PFS First Choice	Volkswriter
Enable	Professional Write	VuWriter
EXP	Q&A Write	Wang OIS
Final Word	Quark XPress	Wang WPS
FullWrite	RagTime MS Works (to ASCII file)	Wang Writer
GemWord Plus	Rich Text Format	Window Works
IBM Writing Assistant	RSG (to ASCII file)	Windows Write
Interleaf	Signature	WiziWord
LaTeX	SLITeX	Wordstar
Latex	SmartWhere	Wordstar 2000
Leading Edge	SmartWrite II	WriteNow
Lotus Manuscript		Xerox
Lotus Write		

Software packages that we are unable to translate:

FrameMaker	Ready, Set, Go
PageMaker	Scientific Writer

Disks produced on IBM or IBM-compatible computers are preferred, but those produced on some Apple or Wang computers can also be converted. Because of the file structures and internal coding, we cannot accept disks created on desktop publishing systems or those created on proprietary typesetting systems. We also cannot guarantee that all special characters can be translated. Tabular and mathematical material, such as equations, will not be captured from the disk but will be rekeyed.

To expedite work and for your own security, we do require that you submit a hard copy printout of the disk file. The tables and equations will be keyed from this hard copy. We also need to know the name of the file to be converted, the type of hardware (e.g., IBM PC) on which the files were created, the operating system (e.g., DOS 3.3), and the version of the software (e.g., WordPerfect 5.1) used to create the file.

<p>PLEASE FILL OUT ALL INFORMATION ON REVERSE SIDE AND SUBMIT THIS FORM WITH YOUR DISK. DISKS WILL NOT BE PROCESSED WITHOUT THIS INFORMATION.</p>
---



## DISK SUBMISSION FORM

AACR journals are now using personal computers to copyedit manuscripts accepted for publication. When submitting a revised manuscript, authors are encouraged to submit an electronic disk of the paper along with the required four hard copy printouts. Disks will ultimately be returned to the authors.

See reverse for the word processing packages that can be accepted.

### File preparation

Please be sure that the file you send is the most recent version of the manuscript and that it matches the most recently submitted printed copy. The file should contain all the parts of the manuscript in **one** file. Mathematical and tabular material, however, will be processed in the traditional manner and may be excluded from the disk file.

Note: AACR does not assume responsibility for errors in conversion of customized software, newly released software, or special characters.

Please label the outside of the disk with the journal name, the first author's name, a partial title of the manuscript, and the name of the computer file used to access the manuscript on disk. To process your disk efficiently, we need the following information. Please be sure to provide **ALL** the information.

**Name used to access paper on disk:** \_\_\_\_\_

**Name of computer used (e.g., IBM/PS2):** \_\_\_\_\_

**Operating system and version (e.g., DOS 3.3):** \_\_\_\_\_

**Word processing program and version (e.g., WordPerfect 5.0):** \_\_\_\_\_

[See reverse for acceptable programs.]


**Manuscript number:** \_\_\_\_\_

**First author:** \_\_\_\_\_

**Corresponding author (if different from first author):** \_\_\_\_\_

**Telephone/FAX numbers:** \_\_\_\_\_

This form (both sides) may be reproduced.



**A Monthly Journal**  
featuring the most innovative  
clinical research and  
translational research bridging  
the laboratory and the clinic.

*Editor-in-Chief:*

**John Mendelsohn,  
M.D.**

Memorial Sloan-Kettering Cancer  
Center

### Subscribe Now!

Every issue is essential  
reading.


Call 1-800-875-2997  
or 201-627-2427,  
or mail back the attached  
order card.

### No-Risk Guarantee:

If you are not entirely  
satisfied with this journal,  
you will receive a refund  
for any unmailed issues  
on your subscription.

## ORDER TODAY!

Don't miss a single issue of the latest clinical and translational research!



An official journal of the American Association for Cancer Research

**ORDER FORM:** Yes! I'd like to subscribe!

#### *Clinical Cancer Research*

Vol. 2, 1996, 12 issues, ISSN 1078-0432

Institutional (Available only as a combined subscription  
with *Cancer Research*)

\$595

\$130 should be added for delivery outside the U.S.

Individual

\$95

\$40 should be added for delivery outside the U.S.

AACR Members: Contact the AACR for rates, (215) 440-9300.

Canada: Add 7% GST. MD: Add state sales tax.

**Individual Subscriber:** I certify that this  
subscription is solely for my personal use and will not be  
used in a library.

SIGNATURE \_\_\_\_\_

NAME \_\_\_\_\_

ADDRESS \_\_\_\_\_

CITY, STATE, ZIP \_\_\_\_\_

COUNTRY \_\_\_\_\_

**ORDER FORM:** Yes! I'd like to subscribe!

#### *Clinical Cancer Research*

Vol. 2, 1996, 12 issues, ISSN 1078-0432

Institutional (Available only as a combined subscription  
with *Cancer Research*)

\$595

\$130 should be added for delivery outside the U.S.

Individual

\$95

\$40 should be added for delivery outside the U.S.

AACR Members: Contact the AACR for rates, (215) 440-9300.

Canada: Add 7% GST. MD: Add state sales tax.

**Individual Subscriber:** I certify that this  
subscription is solely for my personal use and will not be  
used in a library.

SIGNATURE \_\_\_\_\_

NAME \_\_\_\_\_

ADDRESS \_\_\_\_\_

CITY, STATE, ZIP \_\_\_\_\_

COUNTRY \_\_\_\_\_

#### Method of Payment

Enclosed check or money order in U.S. dollars drawn  
on U.S. bank. Payable to American Association for  
Cancer Research.

Institutional purchase order # \_\_\_\_\_  
is enclosed

Please charge my  Mastercard  VISA  
 American Express

ACCOUNT NAME \_\_\_\_\_

ACCOUNT NO. \_\_\_\_\_

EXPIRATION DATE \_\_\_\_\_

SIGNATURE \_\_\_\_\_

Please send me *Instructions for Authors*.

#### Method of Payment

Enclosed check or money order in U.S. dollars drawn  
on U.S. bank. Payable to American Association for  
Cancer Research.

Institutional purchase order # \_\_\_\_\_  
is enclosed

Please charge my  Mastercard  VISA  
 American Express

ACCOUNT NAME \_\_\_\_\_


ACCOUNT NO. \_\_\_\_\_

EXPIRATION DATE \_\_\_\_\_

SIGNATURE \_\_\_\_\_

Please send me *Instructions for Authors*.

Order This Important New Journal Today!



An official journal of the American Association for Cancer Research



NO POSTAGE  
NECESSARY  
IF MAILED  
IN THE  
UNITED STATES

**BUSINESS REPLY MAIL**  
FIRST CLASS PERMIT NO. 724 EASTON, MD

POSTAGE WILL BE PAID BY ADDRESSEE

CLINICAL CANCER RESEARCH  
PO BOX 3000  
DENVER NJ 07834-9359



NO POSTAGE  
NECESSARY  
IF MAILED  
IN THE  
UNITED STATES

**BUSINESS REPLY MAIL**  
FIRST CLASS PERMIT NO. 724 EASTON, MD

POSTAGE WILL BE PAID BY ADDRESSEE

CLINICAL CANCER RESEARCH  
PO BOX 3000  
DENVER NJ 07834-9359



**A Monthly Journal**

featuring the most innovative clinical research and translational research bridging the laboratory and the clinic.

*Editor-in-Chief:*

**John Mendelsohn, M.D.**

Memorial Sloan-Kettering Cancer Center

**Subscribe Now!**

Every issue is essential reading.

Call 1-800-875-2997

or 201-627-2427,

or mail back the attached order card.

**No-Risk Guarantee:**

If you are not entirely satisfied with this journal, you will receive a refund for any unmailed issues on your subscription.

## AMERICAN ASSOCIATION FOR CANCER RESEARCH

The American Association for Cancer Research (AACR) is a professional society of over 11,000 scientists and physicians involved in all aspects of basic, clinical, and translational cancer research. Members of the AACR enjoy

- subscriptions to *Cancer Research*, *Cell Growth & Differentiation (CG&D)*, *Cancer Epidemiology, Biomarkers & Prevention*, and *Clinical Cancer Research* at reduced member rates
- reduced registration rates at the AACR Annual Meeting, Special Conferences, and International Meetings
- Employment Register, Directory of Members, public education activities, and many other benefits

Special programs to provide enhanced career development opportunities for minority scientists include

- **Session on Career Development at Annual Meeting**
- **Mentorship Program**
- **Travel Awards to Scientific Meetings**

**American Association for Cancer Research**  
Public Ledger Building, Suite 816  
150 S. Independence Mall West  
Philadelphia, PA 19106-3483  
Telephone: (215) 440-9300  
FAX: (215) 440-9313 / E-Mail: [aacr@aol.com](mailto:aacr@aol.com)

## MAYO CLINIC DIVISION OF MEDICAL ONCOLOGY AND MAYO CANCER CENTER

### Clinical Research Positions

The Division of Medical Oncology and the NCI-designated Mayo Cancer Center in Rochester, Minnesota, invite applications for two clinical research positions. Clinical investigators with established cancer research programs are encouraged to apply. The Mayo Clinic provides an outstanding environment for investigators interested in conducting translational research with the goal of improving prevention, diagnosis, and treatment of cancer. Interested applicants should submit a statement of research interests, curriculum vitae, bibliography, and list of references to:

James N. Ingle, M.D.  
Associate Director for Clinical Research  
Mayo Cancer Center  
Mayo Clinic  
200 First Street, SW  
Rochester, MN 55905



*Mayo Foundation is an affirmative action and equal opportunity educator and employer.*

THE SURGERY BRANCH, NATIONAL CANCER INSTITUTE, NIH, IS SEEKING PATIENTS FOR ONGOING CLINICAL TREATMENT PROGRAMS.

PATIENTS WITH THE FOLLOWING MALIGNANCIES ARE BEING TREATED UNDER COMBINED MODALITY OR INNOVATIVE IMMUNOTHERAPY PROGRAMS:

- METASTATIC MELANOMA AND KIDNEY CANCER •
- STAGE II OR LOCALLY ADVANCED BREAST CANCER •
- METASTATIC COLORECTAL CANCER TO THE LIVER •
- LOCOREGIONAL GASTRIC OR PANCREATIC CANCER •
- MESOTHELIOMA, PULMONARY METASTASES, STAGE IIIA, B LUNG CANCER  
OR ESOPHAGEAL CANCER •
- LOCALIZED SOFT TISSUE SARCOMAS •
- PERITONEAL CARCINOMATOSIS •



CARE FOR ALL PATIENTS IS PROVIDED AT THE CLINICAL CENTER, NIH, BETHESDA, MARYLAND.

FOR MORE INFORMATION ON CANCER PROGRAMS, PLEASE CALL  
(301) 496-1533

*A PUBLIC SERVICE ANNOUNCEMENT COURTESY OF THIS PUBLICATION*



## Our search engine is roughly 17,000 times faster than the one you've probably been using.

And, dare we say, just as friendly.

Introducing Oncology Online. The Internet service that gives you easy, immediate access to the most comprehensive source of pharmaceutical, clinical and therapeutic information. Without having to leave your office.

Oncology Online brings you free, unrestricted access to MEDLINE®, CANCERLIT®, PDQ®, AIDSLINE® and

HEALTH®. Plus a full-text library of oncology journals and up-to-date oncology and medical news.

And you can search them all in plain English, not computer language.

Oncology Online also gives you secure, physician-only access to interactive forums in all cancer subspecialties, CME seminar listings and hotlinks to over 100 medical school and

cancer center sites via the Internet.

With Oncology Online, the data you need is there right now. After all, spending less time in the library just may add time where it really counts.

❖ Ours is a free service. To log on immediately: <http://medserv.com> or call 1.800.665.4679 and find out

how to get online fast.